Impact of Hyperoncotic Albumin to Support Blood Loss Replacement

NCT03848507 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

24

Enrollment

OTHER

Sponsor class

Conditions

Blood Loss, Surgical
Fluid Retention

Interventions

DRUG: albumin 20%

Sponsor

Insel Gruppe AG, University Hospital Bern